Healthcare and pharma ad spending will eclipse $30B this year: Even as advertisers spend more on digital channels, traditional media will remain a big focus for healthcare and pharma due to the older demographics they target.
Hispanic consumers seek health information from non-traditional channels: This is due to a lack of trusted health resources for this community. Healthcare and pharma marketers need to craft culturally relevant content.
Eli Lilly’s blockbuster GLP-1 sales fell short of expectations in Q3: The pharma giant blames wholesalers for not buying more drugs. We think the rise of compounded GLP-1s is also a factor.
On today’s podcast episode, we discuss why mega-pharmacies are struggling, why 7-Eleven is closing and opening a lot of stores, and what the new model of convenience will look like. Tune in to the discussion with Senior Director of Podcasts and host Marcus Johnson and Senior Analysts Blake Droesch and Rajiv Leventhal.
Walgreens expands D2C telehealth to 30 states: We examine how the move aligns with Walgreens’ strategy to rightsize its retail pharmacy business.
GoodRx moves into health and wellness e-commerce: We explore why GoodRx could be a good distribution channel for consumer health and pharma brands.
Oracle unveils AI-powered EHR system: We think it could help the vendor capture market share from smaller players in the space because convincing Epic’s customers to switch platforms will be a tough sell.
Peloton stock jumps by double digits: The connected fitness company’s focus on profitability is paying off, with Q1 FY25 revenues cleanly surpassing expectations.
The vertical’s spending on digital advertising will surge 12.5% this year, driven by a 14.2% spike in pharma, per our estimates.
OpenAI’s Whisper often hallucinates harmful content, challenging its suitability for healthcare applications where accuracy is critical to patient safety.
Most digital hypertension tools are not cost-effective: Healthcare orgs will be less likely to invest in health tech solutions as more evidence questions their value.
Half of insured patients can’t predict their Rx costs: It’s causing some to abandon their meds. Big Pharma must provide more resources to improve adherence rates.
Pfizer raises full-year revenue guidance by $1.5B: The drugmaker’s Q3 earnings represent a near-term win, but one quarter of strong performance won’t appease its activist investor for long.
Senators probe Pfizer, Eli Lilly about their D2C telehealth platforms: But we don’t expect a slowdown in Big Pharma’s push into direct-to-consumer sales. Here’s why.
Failure to secure patient data on a vast scale underscores how neglected safeguards put sensitive health information at risk.
Haleon debuts AI-powered screening tool for advertising: Marketers are failing to connect with diverse audiences. They’ll need to focus on AI-driven personalization to create resonant content.
Patients prefer AI-generated messages in their EHR: We unpack the results of new research that highlights AI’s ability to show empathy in patient communications.
AI dominates HLTH conference: We explore the most significant AI news from the event and examine why some health systems feel a sense of urgency to invest in AI.
Some health systems scale back telehealth offerings: But trimming virtual care too much may cause patients to flee to competing healthcare providers.
Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.